The Totality of Evidence and Use of ABP 215, a Biosimilar to Bevacizumab

ABP 215 (MVASI™, Amgen, Thousand Oaks, CA; MVASI™, Amgen Europe B.V., Netherlands) is a biosimilar to bevacizumab (Avastin(®), Genentech, South San Francisco, CA) reference product (RP), a monoclonal antibody targeting vascular endothelial growth factor A (VEGF-A). Here we provide a brief overview o...

Descripción completa

Detalles Bibliográficos
Autores principales: Goldschmidt, Jerome, Hanes, Vladimir
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Healthcare 2020
Materias:
Practical Approach
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8140169/
https://www.ncbi.nlm.nih.gov/pubmed/33336310
http://dx.doi.org/10.1007/s40487-020-00133-1

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8140169/
https://www.ncbi.nlm.nih.gov/pubmed/33336310
http://dx.doi.org/10.1007/s40487-020-00133-1

Ejemplares similares